News

INVESTIGATION REMINDER: Schall regulation agency declares it’s investigating claims towards Utilized Therapeutics, Inc. and encourages traders with $ 100,000 losses to contact the agency – Enterprise Wire

investigation-reminder-schall-regulation-agency-declares-its-investigating-claims-towards-utilized-therapeutics-inc-and-encourages-traders-with-100000-losses-to-contact-the-agency-enterprise

LOS ANGELES–(BUSINESS WIRE) – Schall law firm, a national shareholder rights law firm, has announced that it has made claims on behalf of investors of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ: APLT) for violations of securities laws.

The investigation focuses on whether the company has made false and / or misleading statements and / or has failed to disclose information that is relevant to investors. Applied Therapeutics announced on August 17, 2020 that the FDA has clinically discontinued its ACTION Kids study of the company's AT-007 compound for the treatment of galactosemia. According to the company, the FDA needs additional technical information related to the study in order for it to proceed. Because of these facts, Applied Therapeutics' stake fell 12% on the same day.

If you are a shareholder who has suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall law firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335 to discuss your rights at no charge. You can also contact us on the company's website at www.schallfirm.com or by email at brian@schallfirm.com.

In this case, the class is not yet certified and you will not be represented by an attorney until certification. If you don't take action, you can remain an absent class member.

Schall law firm represents investors around the world and specializes in class actions and shareholder disputes.

This press release may be viewed as a solicitor advertisement in some jurisdictions under applicable laws and ethical rules.

0 Comments
Share

labsurlab

Reply your comment

Your email address will not be published. Required fields are marked*